Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC

Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer

Research Question:
Does the drug delivery system, TAR-200, safe and tolerable in patients with bladder cancer?

Basic Study Information

The purpose of this study is to determine if TAR-200, an investigational drug delivery system, in combination with nivolumab, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are scheduled for radical cystectomy (RC).

Location: University of Rochester Medical Center

Study Contact Information

Study Coordinator: Peter MacDowell
Phone: (585) 276-3450

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search